Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
11 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to ADMA Biologics Inc’s names, not what it holds today.
Patents granted
11
11 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 1 in 2023
Applications published
14
since 2001, to Dec 31, 2025
Names they are printed under
4
its own name, a subsidiary
By yearGrantedApplications published
'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
ADMA Biologics, Inc. its own name
named as the applicant on its applications, in US
11 publishedADMA BIOLOGICS, INC. its own name
US, as the owner printed on each patent
1 publishedADMA BIOMANUFACTURING, LLC a subsidiary
US, as the owner printed on each patent
0 publishedADMA BIOMANUFACTURING, LLC a subsidiary
named as the applicant on its applications, in US
2 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Nov 18, 2025 | 12,473,351 | Compositions and methods for the treatment of immunodeficiency | Biotechnology | ADMA BIOMANUFACTURING, LLC |
| Feb 13, 2024 | 11,897,943 | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection | Biotechnology | ADMA BIOMANUFACTURING, LLC |
| Oct 10, 2023 | 11,780,906 | Compositions and methods for the treatment of immunodeficiency | Biotechnology | ADMA BIOMANUFACTURING, LLC |
| May 24, 2022 | 11,339,206 | Compositions and methods for the treatment of immunodeficiency | Biotechnology | ADMA BIOMANUFACTURING, LLC |
| Aug 10, 2021 | 11,084,870 | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection | Biotechnology | ADMA BIOLOGICS, INC. |
| Jun 16, 2020 | 10,683,343 | Compositions and methods for the treatment of immunodeficiency | Biotechnology | ADMA BIOLOGICS, INC. |
| Apr 16, 2019 | 10,259,865 | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection | Biotechnology | ADMA BIOLOGICS, INC. |
| May 15, 2018 | 9,969,793 | Compositions and methods for the treatment of immunodeficiency | Biotechnology | ADMA BIOLOGICS, INC. |
| Nov 14, 2017 | 9,815,886 | Compositions and methods for the treatment of immunodeficiency | Biotechnology | ADMA BIOLOGICS, INC. |
| Jul 25, 2017 | 9,714,283 | Compositions and methods for the treatment of immunodeficiency | Biotechnology | ADMA BIOLOGICS, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Aug 8, 2024 | 2024/0262896 | ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTION | Biotechnology | ADMA BIOMANUFACTURING, LLC |
| Feb 8, 2024 | 2024/0043503 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY | Biotechnology | ADMA BIOMANUFACTURING, LLC · patent 12,473,351 granted from it |
| Dec 22, 2022 | 2022/0403008 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY | Biotechnology | ADMA Biologics, Inc. · patent 11,780,906 granted from it |
| Feb 3, 2022 | 2022/0034885 | COMPOSITIONS AND METHODS FOR DETERMINING CORONAVIRUS NEUTRALIZATION TITERS | Analysis of biological materials | ADMA Biologics, Inc. |
| Jan 27, 2022 | 2022/0023339 | ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTION | Biotechnology | ADMA BIOLOGICS, INC. · patent 11,897,943 granted from it |
| Sep 9, 2021 | 2021/0277093 | IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS OF PRODUCTION FOR CORONAVIRUS | Pharmaceuticals | ADMA Biologics, Inc. |
| May 6, 2021 | 2021/0130441 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY | Biotechnology | ADMA Biologics, Inc. · patent 11,339,206 granted from it |
| Feb 4, 2021 | 2021/0034720 | AUTOMATED DOCUMENT MANAGEMENT SYSTEM | Computer technology | ADMA Biologics, Inc. |
| Aug 8, 2019 | 2019/0241646 | ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTION | Biotechnology | ADMA Biologics, Inc. · patent 11,084,870 granted from it |
| Sep 20, 2018 | 2018/0265574 | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection | Biotechnology | ADMA Biologics, Inc. · patent 10,259,865 granted from it |
What it applied for, 2024 to 2025: Biotechnology 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.